Akums Drugs and Pharmaceutical (AKUMS) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Akums Drugs and Pharmaceutical stock ₹367, price ₹770, that is 52.4% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
27‑month range ₹412.08 – ₹1,115 · fair‑value band ₹275.02 – ₹458.37 · the ₹769.85 price screens above the ₹366.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Akums Drugs and Pharmaceutical in your weekly email
Every Wednesday you see whether Akums Drugs and Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally.
Show moreShow less
The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds.
It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology.
In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
Stock analysis
Akums Drugs and Pharmaceutical (AKUMS) currently trades at ₹769.85, while our model-based Fair Value estimate is ₹366.69, 52% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ₹645.47 per share, and 2 of the 24 models we run sit above the ₹769.85 price.
Bear case: the Asset-Based group reads lowest at ₹93.16, and 22 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹275.02 (bear) to ₹458.37 (bull), the price of ₹769.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Akums Drugs and Pharmaceutical reported revenue of ₹43.6B in FY2026 versus ₹36.5B in FY2022, a compound +4.6%/yr. Reported net income was ₹2.6B in FY2026.
Key figures
Market cap ₹118B (≈ $1.3B) Small · P/E ratio 32.4 · P/S ratio 2.44 · EPS (TTM) ₹23.76 · Net margin 7.5% · Return on equity 10.9% · Return on assets (EBIT) 8.2% (5-year average) · Operating margin 13.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 87% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −52%, AKUMS screens richer than that median.
Fair Value models
Bear₹275.02Fair Value ₹366.69Bull₹458.37
Price ₹769.85 · Downside -52.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹14.71 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+40.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+40.4%
Dividend (yield on the price)0.0%
Growth Forecast
Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −0.8% a year for the price and +8.6% for the forecasts.
Compare Akums Drugs and Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−52.4% · Bottom 25%
Profitability
Return on equity (12 months)10.9% · Above median
Return on assets4.7% · Above median
Net margin (12 months)7.5% · Above median
Operating margin (12 months)13.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)34.8% · Top 25%
Dividend yield (12 months)0.0% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)32.4× · Pricier than median
P/B3.56× · Priciest 25%
P/S (12 months)2.44× · Pricier than median
Price / free cash flow (fiscal year)12.0× · Cheaper than median
EV/EBITDA17.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)100· sector 25
PAST (return on equity)44· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Akums Drugs and Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/AKUMS
Frequently asked questions
Is Akums Drugs and Pharmaceutical (AKUMS) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ₹366.69 versus a price of ₹769.85, about 52% lower (overvalued).
What is the fair value of AKUMS?
Our model-based fair value for Akums Drugs and Pharmaceutical is ₹366.69 (as of Nov 6, 2026), built from audited fundamentals. The current price: ₹769.85.
What is the quality score of AKUMS?
Akums Drugs and Pharmaceutical has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Akums Drugs and Pharmaceutical (AKUMS)?
Our model-based price target is the fair value of ₹366.69 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario ₹275.02, optimistic scenario ₹458.37. It is a calculation from audited fundamentals, not an analyst target.
What is the Akums Drugs and Pharmaceutical stock forecast for 2026?
Our models put fair value at ₹366.69, about 52% lower versus a price of ₹769.85 (overvalued). Cautious scenario ₹275.02, optimistic scenario ₹458.37. The calculation is refreshed regularly with new filings.
What is the revenue of Akums Drugs and Pharmaceutical (AKUMS)?
Akums Drugs and Pharmaceutical reported trailing-twelve-month revenue of about ₹48.3B (latest available figure, as of Nov 6, 2026).
What growth is priced into Akums Drugs and Pharmaceutical (AKUMS)?
For today's price to be fair in a discounted-cash-flow model, Akums Drugs and Pharmaceutical would have to grow free cash flow by +3.4 % per year for five years (discount rate 12.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +4.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of AKUMS use?
Our models discount Akums Drugs and Pharmaceutical at 12.5 %: a base by market capitalisation (small), damped by beta 0.62, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Akums Drugs and Pharmaceutical that is +3.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.5 %) and the same formula as our fair value.
How much growth has Akums Drugs and Pharmaceutical (AKUMS) delivered so far?
Over the past 4 years revenue at Akums Drugs and Pharmaceutical grew +4.6 % a year. The price currently implies free-cash-flow growth of +3.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Akums Drugs and Pharmaceutical (AKUMS) growing?
The median revenue growth in the sector is +1.5 % a year. That is the yardstick for the growth priced into Akums Drugs and Pharmaceutical (+3.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Akums Drugs and Pharmaceutical (AKUMS)?
The free-cash-flow yield on the price is 8.32 %: that much free cash flow Akums Drugs and Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (12.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Akums Drugs and Pharmaceutical (AKUMS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Akums Drugs and Pharmaceutical it is ₹366.69 per share (as of Nov 6, 2026), against a price of ₹769.85. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Akums Drugs and Pharmaceutical stock overvalued or undervalued in 2026?
As of Nov 6, 2026, AKUMS trades above its calculated fair value: price ₹769.85, fair value ₹366.69, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AKUMS?
No. The price is what the market pays today (₹769.85); the fair value is what the company's own numbers justify (₹366.69). For Akums Drugs and Pharmaceutical the two are ₹403.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Akums Drugs and Pharmaceutical worth?
The market values Akums Drugs and Pharmaceutical at about ₹118B (market capitalisation, as of Nov 6, 2026). Per share that is ₹769.85; our models calculate a fair value of ₹366.69 per share.
What do the bullish and bearish scenarios say about AKUMS?
Our models span a range for Akums Drugs and Pharmaceutical: cautious scenario ₹275.02, base ₹366.69, optimistic ₹458.37 per share (as of Nov 6, 2026, price ₹769.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AKUMS?
Akums Drugs and Pharmaceutical trades at a price-to-earnings ratio of 32.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹366.69 is built from several models across several years. Other multiples: P/B 3.6, P/S 2.4, EV/EBITDA 17.4.
How solid is the balance sheet of Akums Drugs and Pharmaceutical (AKUMS)?
Balance-sheet figures for Akums Drugs and Pharmaceutical (as of Nov 6, 2026): return on equity 10.9%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is AKUMS from its 52-week high?
Akums Drugs and Pharmaceutical trades at ₹769.85, about 6% below its 52-week high of ₹823.30 and 87% above the low of ₹412.08 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹366.69 is for.
Which stocks are comparable to Akums Drugs and Pharmaceutical?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Akums Drugs and Pharmaceutical stock attractive at the current price?
The data as of Nov 6, 2026: price ₹769.85, calculated fair value ₹366.69 (−52%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AKUMS calculated?
We run Akums Drugs and Pharmaceutical through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹366.69 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Akums Drugs and Pharmaceutical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Akums Drugs and Pharmaceutical (AKUMS)?
The closing price on Nov 11, 2026 was ₹769.85. Our model-based fair value is ₹366.69, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Akums Drugs and Pharmaceutical right now?
The price sits above even our optimistic bull case (₹458.37). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Akums Drugs and Pharmaceutical
How large is the market capitalisation of Akums Drugs and Pharmaceutical (AKUMS)?
The market capitalisation of Akums Drugs and Pharmaceutical is ₹118B (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Akums Drugs and Pharmaceutical (AKUMS)?
The price-to-sales ratio of Akums Drugs and Pharmaceutical is 2.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Akums Drugs and Pharmaceutical (AKUMS)?
Earnings per share at Akums Drugs and Pharmaceutical are ₹23.76 (price ÷ EPS = P/E 32.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Akums Drugs and Pharmaceutical (AKUMS)?
The net margin of Akums Drugs and Pharmaceutical is 7.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Akums Drugs and Pharmaceutical (AKUMS)?
The return on equity (ROE) of Akums Drugs and Pharmaceutical is 10.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Akums Drugs and Pharmaceutical (AKUMS)?
On an EBIT basis the return on assets of Akums Drugs and Pharmaceutical is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Akums Drugs and Pharmaceutical (AKUMS)?
The operating margin of Akums Drugs and Pharmaceutical is 13.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Akums Drugs and Pharmaceutical (AKUMS)?
Revenue at Akums Drugs and Pharmaceutical is growing +34.8% versus a year earlier (3y avg +7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Akums Drugs and Pharmaceutical (AKUMS)?
Earnings per share at Akums Drugs and Pharmaceutical are growing +177% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Akums Drugs and Pharmaceutical (AKUMS) hold?
Akums Drugs and Pharmaceutical holds more cash than debt, ₹2.3B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Akums Drugs and Pharmaceutical in the live analysis
One click puts Akums Drugs and Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026